State Street Corp Trims Position in MiMedx Group, Inc. (NASDAQ:MDXG)

State Street Corp reduced its position in MiMedx Group, Inc. (NASDAQ:MDXG) by 2.7% in the 3rd quarter, Holdings Channel reports. The fund owned 3,860,148 shares of the company’s stock after selling 107,819 shares during the period. State Street Corp’s holdings in MiMedx Group were worth $22,813,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of the business. Victory Capital Management Inc. grew its position in shares of MiMedx Group by 909.0% in the second quarter. Victory Capital Management Inc. now owns 138,449 shares of the company’s stock valued at $959,000 after purchasing an additional 124,727 shares during the period. Farther Finance Advisors LLC boosted its stake in MiMedx Group by 88.6% in the 3rd quarter. Farther Finance Advisors LLC now owns 24,599 shares of the company’s stock worth $145,000 after buying an additional 11,557 shares during the last quarter. Isthmus Partners LLC grew its holdings in MiMedx Group by 30.4% in the 2nd quarter. Isthmus Partners LLC now owns 393,214 shares of the company’s stock valued at $27,000 after buying an additional 91,714 shares during the period. Harbor Capital Advisors Inc. increased its stake in shares of MiMedx Group by 299.9% during the 3rd quarter. Harbor Capital Advisors Inc. now owns 1,027,738 shares of the company’s stock valued at $6,074,000 after acquiring an additional 770,744 shares during the last quarter. Finally, Dimensional Fund Advisors LP lifted its holdings in shares of MiMedx Group by 47.0% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,292,822 shares of the company’s stock worth $8,958,000 after acquiring an additional 413,443 shares during the period. 79.15% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, StockNews.com lowered shares of MiMedx Group from a “strong-buy” rating to a “buy” rating in a research report on Friday, November 8th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $12.00.

MiMedx Group Trading Up 0.2 %

Shares of MDXG stock opened at $9.10 on Monday. MiMedx Group, Inc. has a fifty-two week low of $5.47 and a fifty-two week high of $10.14. The firm’s 50 day moving average price is $8.01 and its two-hundred day moving average price is $7.09. The stock has a market cap of $1.34 billion, a price-to-earnings ratio of 16.55 and a beta of 1.98. The company has a quick ratio of 3.53, a current ratio of 4.10 and a debt-to-equity ratio of 0.10.

MiMedx Group Company Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.